MANCHESTER, England, 3 June 2019—A trio of myopia management visionaries has been honored with the prestigious British Contact Lens Association (BCLA) Industry Award for their work developing, researching and commercializing the innovative CooperVision® MiSight® 1 day contact lens. John Phillips, Stuart Cockerill and Paul Chamberlain were recognized on Saturday evening at the BCLA Clinical Conference & Exhibition closing gala dinner, selected from a field of finalists who have all made immeasurable contributions to the field.
Myopia is projected to affect the vision and ocular health of approximately five billion people by 2050, more than doubling today’s numbers1. The rising prevalence of this condition, also known as nearsightedness or short-sightedness, is sparking the need to go beyond solely providing vision correction, to also deliver accessible, effective methods to slow the progression of myopia in children.
These factors led the three pioneers to each play a substantial role in developing and commercializing the MiSight® 1 day contact lens2, which is now worn by more than 10,000 children around the world.
The story begins at the University of Auckland (New Zealand), where researcher John Phillips became aware of early experiments demonstrating that myopic defocus imposed on the retina slowed eye growth. He initiated human studies of monovision spectacle wear in children, which demonstrated that myopic defocus could also slow the rate of myopia progression in children. John translated these early experimental optical designs into a dual-focus contact lens with two simultaneous image planes: one focused on the retina to address visual acuity and the other deliberately creating simultaneous myopic defocus on the retina to slow myopia progression.
John’s firm belief in his technology, just as the world was starting to awaken to the increasing prevalence of myopia, led to the adoption of dual-focus technology by CooperVision. Now internationally recognized as a pioneer in the development of optical designs to slow myopic progression, he continues to work on this global challenge as Principal Investigator at the Auckland Myopia Laboratory and Senior Lecturer in the School of Optometry and Vision Science at The University of Auckland.
In 2009, MiSight® 1 day was the first contact lens introduced for myopia management3. At the time, the pathological consequences of myopia were less well established. CooperVision’s Stuart Cockerill had the foresight to initiate the first industry-supported three-year study4 to assess the efficacy of the dual-focus design across three continents, with sites in Canada, Singapore, the United Kingdom and Portugal. This was critical to illustrate the benefits of myopia management to the ophthalmic profession, as well as to align commercial interests on the importance of myopia management for long-term pediatric vision and health.
The study is becoming recognized as a benchmark in its class, with its randomized, controlled, parallel, prospective design. Now in its sixth year, it is the longest continuous monitoring of soft contact lens wearers undertaken in children. The strong, robust evidence base derived from the clinical study continues to inform eye care professionals (ECPs) who are participating in myopia management. Stuart is now Head of Global Commercial Operations, Specialty EyeCare, CooperVision.
The third phase of the groundbreaking product’s evolution has been spearheaded by Paul Chamberlain as CooperVision’s research & development lead for myopia management programs. He directed the analysis of the MiSight® 1 day three-year study, ensuring a rigorous approach with data that was robust and generalizable to the targeted patient population, as well as suitability to support key regulatory pathways. He presented five-year results in Manchester during the BCLA Conference4. Understanding that the interest in this data would be without precedent, his efforts certified that the results and their presentation would withstand the warranted scrutiny.
Paul has also been instrumental in using the study data to translate the innovative technology into everyday practice, highlighting information and insights to assist implementation by ECPs. His work has led to a deeper understanding about the optical principles that underpin dual-focus technology. He is lead author on a forthcoming peer review publication describing the three-year results as well as leading the continuation of the original study to prove continued efficacy, later treatment benefit and the understanding of the post-treatment effect from an optical intervention approach. Paul currently serves as Director, Research Programs, CooperVision.
“Myopia management has been described as the ‘next contact lens revolution’—something more evident than ever at this year’s BCLA Conference. However, it takes inspiration, vision and dedication to integrate new technology into a commercially viable approach,” said James Gardner, Vice President, Global Myopia Management for CooperVision. “The foresight and years of effort from John, Stuart and Paul are well deserving of recognition from their peers and the industry. Yet they’ll be the first to tell you the honor is not about them—it’s about the thousands of children who are benefiting from that work every day. It’s this attitude that gives us hope that we can truly make an impact, working alongside ECPs to take on myopia.”
# # #
1Holden et al, - Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-1042
2 MiSight® 1 day contact lenses are currently available for sale in Canada, the United Kingdom, France, Spain, Portugal, Netherlands, Belgium, Germany, Austria, Switzerland, the Nordic Region, Singapore, Malaysia, Hong Kong, Australia and New Zealand. MiSight® 1 day is not approved in the United States.
3 Hong Kong, 2009.
4 Chamberlain P, Logan N, Jones D, Gonzalez-Meijome J, Saw S-M, Young G. Clinical evaluation of a dual-focus myopia control 1 day soft contact lens: 3-year results (2016 American Academy of Optometry Annual Meeting) and 5-year results (2019 BCLA Clinical Conference & Exhibition).
CooperVision, a unit of The Cooper Companies, Inc. (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit coopervision.com.
About The Cooper Companies
The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in Pleasanton, Calif., Cooper has more than 12,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Mike McDougall, APR, Fellow PRSA
McDougall Communications for CooperVision, Inc.
email@example.com or +1-585-545-1815 (mobile)